Biogen (BIIB) PT Raised to $369 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
April 26, 2018 1:49 AM EDTCantor Fitzgerald lowered its price target on Biogen (NASDAQ: BIIB) to $272.00 (from $289.00) while maintaining a Neutral rating.
... MoreBiogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Biogen (BIIB) PT Lowered to $325 at Leerink Partners
April 25, 2018 6:37 AM EDTLeerink Partners lowered its price target on Biogen (NASDAQ: BIIB) to $325.00 (from $365.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) PT Lowered to $385 at Guggenheim
April 25, 2018 2:03 AM EDTGuggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
... MoreUPDATE: Baird Upgrades Biogen (BIIB) to Outperform
April 25, 2018 1:08 AM EDT(Updated - April 25, 2018 4:37 AM EDT)
(updated to add analyst comment)
Baird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $323.00.
Analyst Brian Skorney comments "While we have all the enthusiasm that goes with... More
UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to Buy
April 25, 2018 12:56 AM EDT(Updated - April 25, 2018 4:39 AM EDT)
(updated to add analyst comment)
Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from Conviction Buy to Buy with a price target of $388.00 (from $396.00).
Analyst Terrance Flynn remains Buy-rated after removing the name from the Conviction Buy... More
Biogen (BIIB) PT Lowered to $353 at Piper Jaffray
April 24, 2018 1:30 PM EDTPiper Jaffray lowered its price target on Biogen (NASDAQ: BIIB) to $353.00 (from $407.00) while maintaining a Overweight rating.
Analyst Chris Raymond comments "Remain Overweight rated on BIIB shares but also lowering estimates, price target after a Q118 top-line miss. Spinraza trends have... More
